Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #43087 on Anavex Life Sciences Corp (AVXL)
Mad Money Monkey
12/07/15 10:38 AM
#43091 RE: tob999 #43087
XenaLives
12/07/15 10:41 AM
#43095 RE: tob999 #43087
If 2-73 is shown to slow the rate of cognitive decline more effectively than solanezumab or aducanumab, Anavex investors can expect terrific gains. If not, however, a complete lack of clinical-stage candidates to fall back on could result in heavy losses. With the extremely limited clinical data to base a decision on, it's hardly worth the risk.